Objective: To observe the curative efficacy of Juanxiao tablets for assistance in treating episodes of bronchial asthma of hot asthma syndrome

and to investigate its influence on levels of interleukin IL-6

IL-8 and IL-10. Method: One hundred and twenty-five patients were randomly divided into the control group (61 cases) and the observation group (64 cases) by a random number table. Patients in the control group received 1-2 spray salbutamol aerosols

and once every 4-8 h when necessary. For heavy patients

Budesonide nasal spray was added

2 sprays to nostrils at morning and evening. Based on the treatment of the control group

patients in the observation group added 8 Juanxiao tablets thrice daily. All patients in both two groups received 2 weeks of treatment. The main symptoms including breathing

chest tightness

cough up phlegm

coughing

wheezing sound and asthma control questionnaire (ACQ) were graded before and after treatment. Lung function indexes such as forced expiratory volume in one second (FEV1)

forced expiratory volume in first second (FEV1/FVC) and forced vital capacity ratio

peak expiratory flow (PEF)

peak expiratory flow rate prediction percentage (PEF%pred) were evaluated. Levels of IL-6

IL-8

IL-10 and peripheral blood eosinophil (EOS) were tested. Result: The clinical efficacy of total effective rate in the observation group was 95.31%

which was superior to that of 81.97% in the control group (P<0.05). After therapy

scores of breathing

chest tightness

cough up phlegm

coughing

wheezing sound in the observation group were lower than those in the control group (P<0.01). The FEV1%pred

FEV1/FVC

PEF

PEF%pred in the observation group were higher than those in the control group (P<0.01). After treatment

levels of IL-6 and IL-8 in the observation group were lower

while IL-10 level was higher than those in the control group (P<0.01). The EOS and ACQ scores in the observation group were inferior to those in the control group (P<0.01). Conclusion: Juanxiao tablets could reduce clinical symptoms

improve lung function and control asthma in treating episode of bronchial asthma at (hot asthma syndrome). Its mechanism may be related to modulating inflammatory factor and reducing airway inflammation.